title: Activity of LaSOM 65, a monastrol-derived compound, against glioblastoma multiforme cell lines.
abstract: OBJECTIVE
  Despite recent progress in glioblastoma treatment, prognosis is still poor. Monastrol is a kinesin spindle protein (KSP) inhibitor and anticancer effects for this molecule have been reported. Here we describe the effect of LaSOM 65, a monastrol derivated compound, against glioma cell lines.
  
  
  METHODS
  Cell counting, viability assay, lactate dehydrogenase (LDH) activity, cell-cycle analysis, immunofluorescence and organotypic hippocampal slice cultures were performed.
  
  
  RESULTS
  LaSOM 65 reduced cell number and cell viability of gliomas cells, but did not cause arrest in the cell cycle at the G2/M phase. Measurement of LDH activity showed that LaSOM 65 induces necrosis after 48 h of treatment.
  
  
  CONCLUSIONS
  LaSOM 65 appears to a be promising new molecule to treat glioblastoma since it promotes a decrease of cell growth and cell viability of glioma cells in vitro and does not induces the neurotoxic characteristics of the anti-mitotic drugs currently used.
authors.affiliation: Ramiro Barcelos Street, 2600 Lab 22. Zip code: 90035-003, Porto Alegre/RS, Brazil. abattastini@gmail.com.
authors.forename: Cristiane Santos
authors.initials: CS
authors.lastname: Stuepp
authors.forename: Fabrício
authors.initials: F
authors.lastname: Figueiró
authors.forename: Franciane Brackmann
authors.initials: FB
authors.lastname: Mendes
authors.forename: Elizandra
authors.initials: E
authors.lastname: Braganhol
authors.forename: Andressa
authors.initials: A
authors.lastname: Bernardi
authors.forename: Rudimar Luiz
authors.initials: RL
authors.lastname: Frozza
authors.forename: Christianne Gazzana
authors.initials: CG
authors.lastname: Salbego
authors.forename: Rômulo Faria Santos
authors.initials: RF
authors.lastname: Canto
authors.forename: Dennis
authors.initials: D
authors.lastname: Russowsky
authors.forename: Vera Lucia
authors.initials: VL
authors.lastname: Eifler-Lima
authors.forename: Ana Maria Oliveira
authors.initials: AM
authors.lastname: Battastini
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005909:Glioblastoma; D006624:Hippocampus / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D009336:Necrosis; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D013871:Thiones / Q000494:pharmacology*; D046509:Tissue Culture Techniques; D014404:Tubulin / Q000378:metabolism
chemical_list: C584768:5-ethoxycarbonyl-6-methyl-4-(3-nitrophenyl)-3,4-dihydropyrimidin-2-(1H)-thione; D000970:Antineoplastic Agents; D011743:Pyrimidines; D013871:Thiones; D014404:Tubulin; D007770:L-Lactate Dehydrogenase
keywords: Glioma; KSP inhibitors; LaSOM 65; antitumor activity